Celldex Therapeutics Closes $345M Public Offering
Analysis based on 11 articles · First reported Apr 01, 2026 · Last updated Apr 06, 2026
The market generally views successful public offerings as positive for the issuing company, as it provides capital for growth and operations. For Celldex Therapeutics, the offering of common stock is expected to fund critical commercial readiness activities and clinical development, which could lead to future revenue streams and increased shareholder value.
Celldex Therapeutics announced the pricing and subsequent closing of an underwritten public offering of 11,896,750 shares of its common stock at $29.00 per share, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of approximately $345 million for Celldex Therapeutics. The company intends to use these proceeds to fund commercial readiness for barzolvolimab, continue clinical and preclinical development of its product candidates, grow its bispecific antibody platform, develop additional clinical pipeline candidates, and for general corporate purposes. Leerink Partners, Toronto-Dominion Bank===TD Cowen, Guggenheim Securities, and Cantor Fitzgerald acted as joint bookrunning managers, with LifeSci Capital and H.C. Wainwright & Co. as co-lead managers.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard